裂谷热疫苗策略:增强RVF Clone 13疫苗的稳定性
本研究评估乳糖和蔗糖稳定剂联合冻干对裂谷热Clone 13减毒活疫苗稳定性的影响,并比较两种新配方疫苗的细胞和体液免疫,同时探究Pheroid®佐剂在美利奴羊中的免疫增强作用。结果显示蔗糖配方在冻干过程中维持更高抗原滴度,所有接种动物均产生可比保护性体液免疫,未观察到不良反应。
要点
- 蔗糖-RVF疫苗的玻璃化转变温度(Tg)为97.0 °C,平均残余水分低于2%。
- 乳糖配方的Tg为83.5 °C,残余水分高于2%。
- 所有接种动物均产生可比保护性体液免疫,未观察到不良反应。
核心结论
- 蔗糖配方在冻干过程中维持更高抗原滴度,两种配方疫苗均诱导可比保护性体液免疫。
研究设计与样本
- 研究评估乳糖和蔗糖稳定剂联合冻干对RVF Clone 13疫苗株稳定性的影响,并在小鼠、豚鼠和美利奴羊中测试新配方疫苗的免疫原性和安全性。
主要发现
- 蔗糖-RVF疫苗的Tg为97.0 °C,平均残余水分低于2%。
- 乳糖配方的Tg为83.5 °C,残余水分高于2%。
- 蔗糖配方在冻干过程中维持更高抗原滴度。
- 所有接种乳糖或蔗糖配方(含或不含Pheroid®佐剂)的动物均产生可比保护性体液免疫。
- 仅接种Pheroid®的动物组未观察到CD8+和CD4+ T细胞增殖及IFN-γ表达。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rift Valley Fever virus (RVFV) causes the zoonotic RVF disease, which results in substantial economic losses in livestock industries. Regular vaccination of livestock against RVF is necessary to generate long-term immunity and avoid the loss of livestock. The live attenuated vaccine based on Clone 13 virus strain has been used to reduce the negative impact of RVF disease. The vaccine strain is heat labile and requires stringent conditions for storage and handling. This research evaluated lactose and sucrose-based stabilizers coupled with lyophilisation to enhance stability of the RVF Clone 13 vaccine strain. The glass transition temperature (Tg) of the sucrose-RVF vaccine was 97.0 °C with average residual moisture of below 2 %. The lactose formulation was characterised with Tg of 83.5 °C and residual moisture of above 2 %. The RVF Clone 13 sucrose-based formulation maintained higher antigen titres during lyophilisation compared to the lactose-formulated vaccine. Cellular-mediated and humoral immunity was evaluated and compared for the two newly formulated vaccines. Pheroid® technology was also investigated as a potential adjuvant and its ability to further enhance the immunogenicity conferred by the RVF Clone 13 vaccine formulations in Merino sheep. No adverse reactions were observed following injection of the vaccine formulations in mice, guinea pigs and Merino sheep. Comparable protective humoral immune responses against RVF were obtained for all animals vaccinated with the lactose and sucrose-based stabilisers with and without the Pheroid® adjuvant. No proliferation of CD8+ and CD4+ T-cells as well as expression of IFN-γ was observed for all animals group vaccinated with Pheroid® only. Specific CD8+ IFN-γ+T-cells were expressed at higher levels compared to the CD4+ IFN-γ+T-cells in the RVF Clone 13 vaccines, suggesting that cellular immunity against RVF is through the Class I antigen presentation pathway.
引用
- Moetlhoa B, Tjale M, Pretorius A, et al. Rift Valley Fever vaccine strategies: Enhanced stability of RVF Clone 13. Vaccine. 2022. PMID: 36593173. doi:10.1016/j.vaccine.2022.12.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。